Nanodroplet PCR Lab-Chip for Clinical Pathogen Detection

Information

  • Research Project
  • 8244515
  • ApplicationId
    8244515
  • Core Project Number
    R44AI065169
  • Full Project Number
    5R44AI065169-04
  • Serial Number
    065169
  • FOA Number
    PA-09-115
  • Sub Project Id
  • Project Start Date
    7/1/2005 - 19 years ago
  • Project End Date
    6/30/2013 - 11 years ago
  • Program Officer Name
    RITCHIE, ALEC
  • Budget Start Date
    4/1/2012 - 12 years ago
  • Budget End Date
    6/30/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    04
  • Suffix
  • Award Notice Date
    3/28/2012 - 12 years ago

Nanodroplet PCR Lab-Chip for Clinical Pathogen Detection

DESCRIPTION (provided by applicant): It is estimated that 2 million health-care associated infections are acquired each year by hospitalized patients resulting in 90,000 deaths and about $4.5 billion in excess health care costs. A large and growing percentage of these infections can be attributed to Staphylococcus aureus and, in particular, to methicillin-resistant S. aureus (MRSA). Rapid PCR-based tests have been developed for screening MRSA in health-care settings, but the high cost and complexity of existing nucleic acid testing platforms have limited their acceptance for routine screening in most health-care settings. The goal of this project is to develop a rapid, low-cost, easy-to-use nucleic acid testing platform that can be deployed for MRSA screening in a wide range of health-care settings. The proposed testing platform is based on Advanced Liquid Logic's digital microfluidics technology which enables programmable micro-manipulation of sub-microliter sized droplets using an electrode array formed on a low-cost and disposable printed circuit board substrate. In Phase I of this project Advanced Liquid Logic developed chip-based methods for rapid thermocycling, real-time PCR detection, magnetic-bead based sample preparation, and reaction preparation and mixing. In Phase II, these results will serve as the foundation for the development of a product prototype nucleic acid analysis system for near-patient and point-of-care use. An MRSA screening test will be developed on the platform and extensively validated in preparation for an FDA submission. Ultimately, additional cartridges could be developed for screening and detection of other health-care associated infections. This lab-on-a-chip platform will offer significant advantages over other approaches in terms of flexibility, scalability, performance and cost. PUBLIC HEALTH RELEVANCE: A system for the detection of methicillin-resistant Staphylococcus aureus will be developed to help control the spread of antibiotic-resistant bacteria in hospital settings.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    981342
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:981342\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ADVANCED LIQUID LOGIC
  • Organization Department
  • Organization DUNS
    140695474
  • Organization City
    RESEARCH TRIANGLE PARK
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    277094025
  • Organization District
    UNITED STATES